Following China, Regulatory Approval Process Begins in India, Another Major Market

Onconic Therapeutics is accelerating its global market expansion by initiating the regulatory approval process for Jakuvou in India, following China last year.


On June 2, Onconic Therapeutics announced that its self-developed new drug Jakuvou (ingredient: zastaprazan) has successfully completed Phase 3 clinical trials for erosive gastroesophageal reflux disease (GERD) in India and has finished filing its New Drug Application (NDA).

Onconic Therapeutics' Jakuvou Achieves Phase 3 Success for Erosive GERD in India View original image

According to market research firm Grand View Research, the Indian market for erosive GERD treatment is estimated to be worth approximately 1.8 trillion won. With a population of 1.46 billion—the largest in the world—and dietary changes driven by economic growth leading to a higher prevalence of related diseases, India is regarded as a market with significant growth potential within the global GERD treatment sector.


India is known for its relatively short review period from NDA submission to approval, so Jakuvou's regulatory approval process is also expected to proceed swiftly. As a result, the company anticipates receiving additional milestone payments during the approval and launch phases, which are expected to contribute to improvements in both revenue and operating profit this year. Furthermore, as commercialization in India becomes more tangible, the potential for generating royalty income in the global market is also increasing.


Since its domestic launch in October 2024, Jakuvou has quickly grown, recording 21.2 billion won in prescription sales in the first quarter of this year and surpassing 8.5 billion won in monthly prescription sales in April. While strengthening its position in the domestic P-CAB market, the company is also pursuing regulatory approval for erosive GERD in China in partnership with local partner Livzon Pharmaceutical. In addition, Onconic Therapeutics is accelerating global business expansion by developing additional indications for Jakuvou.



A representative from Onconic Therapeutics stated, "Jakuvou has rapidly solidified its presence in the domestic market since its launch, and is now showing tangible development and commercialization achievements in major overseas markets. Based on royalties and milestone payments resulting from its success as a global new drug, we will reinvest in R&D to develop our next innovative drugs—creating a virtuous cycle and continuing our growth as a Gilead-style 'profitable biotech' company."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing